Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Jagriti Craig"'
Autor:
Catherine Najem, Jagriti Craig, Lisa Christopher-Stine, Federico Zazzetti, Wim Noel, Sindhu Ramchandren, Christopher Blango, Chetan S. Karyekar, Rohit Aggarwal
Publikováno v:
Wednesday, April 26.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0f6b2fa982b1d4e9145939c37134b564
https://doi.org/10.1212/wnl.0000000000202419
https://doi.org/10.1212/wnl.0000000000202419
Autor:
Jagriti Craig, Jingwei Li, George Capuano, David C. Wheeler, Vlado Perkovic, Hiddo J.L. Heerspink, David M. Charytan, Rajiv Agarwal, Gian Luca Di Tanna, Hong Zhang, Adeera Levin, Megumi Oshima, Dick de Zeeuw, Meg Jardine, Bruce Neal, Yshai Yavin
Publikováno v:
256.e1
American Journal of Kidney Diseases, 79(2), Pages 244-256.e1. W B SAUNDERS CO-ELSEVIER INC
American Journal of Kidney Diseases, 79(2), Pages 244-256.e1. W B SAUNDERS CO-ELSEVIER INC
RATIONALE AND OBJECTIVE: Canagliflozin reduced the risk of kidney failure and related outcomes in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) in the CREDENCE trial. This analysis of CREDENCE trial data examines the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fb7c8093a9c47ae1fdc639386887ab6
https://pubmed.ncbi.nlm.nih.gov/34029680
https://pubmed.ncbi.nlm.nih.gov/34029680
Autor:
George Capuano, Jagriti Craig, Leonard Chuck, Julio Rosenstock, Manuel González-Ortiz, Kate Merton, Rong Qiu
Publikováno v:
Diabetes Care. 39:353-362
OBJECTIVE This study assessed the efficacy/safety of canagliflozin (CANA), a sodium–glucose cotransporter 2 (SGLT2) inhibitor, plus metformin extended-release (MET) initial therapy in drug-naïve type 2 diabetes. RESEARCH DESIGN AND METHODS This 26
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::353162ad1fac33f16bacfec07c99df5b
https://doi.org/10.2337/dc15-1736
https://doi.org/10.2337/dc15-1736